This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Fragile X syndrome	Phosphoinositide 3-kinase (PI3K)	<p><i>In vitro</i> studies suggest that inhibiting PI3K could help treat Fragile X syndrome. In hippocampal neurons from <i>fragile X mental retardation 1 (Fmr1)</i> knockout mice, a PI3K inhibitor restored synaptic protein translation and dendritic spine density to wild-type levels. Next steps include testing the ability of PI3K inhibitors to rescue behavioral impairments in mice.</p> <p>At least eight companies have PI3K inhibitors in clinical trials for indications outside of neurology.</p> <p>SciBX 3(34); doi:10.1038/scibx.2010.1044 Published online Sept. 2, 2010</p>	Patent filed; available for licensing	<p>Gross, C. <i>et al. J. Neurosci.</i>; published online Aug. 11, 2010; doi:10.1523/JNEUROSCI.0402-10.2010</p> <p>Contact: Gary J. Bassell, Emory University, Atlanta, Ga. e-mail: gbassel@emory.edu</p>